Strategic partnership with global hospitality platform provider active across 26 countries positions company for significant international hotel market expansionSUNNYVALE, Calif., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Actelis Networks, Inc. (NASDAQ: ASNS) ("Actelis" or the "Company"), a market leader in cyber-hardened, rapid deployment networking solutions for IoT and broadband applications, today announced it has received its first customer order for deployment of its GigaLine hospitality solution. The order i ...

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO, Dec. 12, 2025 (GLOBE NEWSWIRE) -- CHAR Technologies Ltd. (“CHAR Tech” or the “Company”) (TSXV:YES), a leader in sustainable energy solutions, is pleased to announce that the Company has closed the order book on its previously announced non-brokered private placement (the “Offering”) of 5,000,000 units (each, a “Unit”) at a price of $0. 20 CAD per Unit for aggregate gross proceeds of$1 million CAD. The Offe ...

Core Viewpoint - The European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion for a higher dose of Wegovy (semaglutide 7.2 mg), which could provide individuals with obesity in the EU a new option for significant weight loss, demonstrating an average weight loss of 20.7% at 72 weeks [1][7]. Summary by Sections Clinical Trial Results - The positive opinion is based on the STEP UP and STEP UP T2D clinical trial programs, showing that one in three participants treated with Wegovy achieved 25% or more weight loss at 72 weeks [2][3]. - In the STEP UP trial, 1,407 adults with a BMI ≥30 kg/m² without diabetes participated, confirming the efficacy and safety of semaglutide 7.2 mg compared to semaglutide 2.4 mg and placebo [5]. - The majority (84%) of the weight lost with Wegovy was from fat mass, with preserved muscle function [2][5]. Health Benefits - Wegovy has proven health benefits in obesity, including significant reductions in the risk of cardiovascular events such as heart attack and stroke, and alleviation of pain from knee osteoarthritis [1][8]. - The new higher dose aims to enhance weight loss while maintaining the established cardiovascular health benefits of Wegovy [7]. Regulatory and Market Implications - The new Wegovy option could be available early in the new year, pending final approval from the European Commission [3]. - Novo Nordisk has also applied for a single-dose device to deliver Wegovy 7.2 mg and is seeking approval in the US, UK, and other countries [3][9].

Core Insights - LOBO Technologies Ltd. has integrated the entire team of Shenzhen Xiangri Technology Co., Ltd. into its subsidiary Jiangsu LOBO, establishing a new Solar Division to enhance its entry into the photovoltaic energy-storage market [1][4] Company Overview - LOBO Technologies Ltd. specializes in electric mobility and smart energy solutions, manufacturing a variety of eco-friendly electric vehicles and home robotic products [5] - The company aims to promote sustainable transportation options that reduce carbon footprints and enhance energy efficiency [5] Team and Expertise - The Shenzhen Xiangri team, founded in 2012, brings over twelve years of experience in the solar PV industry, focusing on manufacturing solar modules and integrated system solutions [2] - The team holds 15 registered patents related to module fabrication processes and system design, covering product development, sales, and installation services [2] Strategic Collaboration - Shenzhen Xiangri has previously collaborated with Jiangsu LOBO, providing energy solutions for solar-powered electric vehicles, which has led to improved performance metrics [3] - Internal testing indicates that the latest PV-storage-charging integrated solution from Shenzhen Xiangri may enhance the range of low-speed electric vehicles by up to 19% [3] Market Opportunities - The African solar market presents significant opportunities for LOBO's solar-storage solutions, necessitating an experienced technical and sales team for successful project execution [3] - LOBO projects that the newly established Solar Division could generate approximately US$5 million in revenue in 2026, depending on market conditions [4] Industry Growth - The global PV-storage industry is experiencing rapid growth, and LOBO's management believes that integrated PV-storage products offer substantial market opportunities [4] - By leveraging Shenzhen Xiangri's technical expertise and market experience, LOBO aims to accelerate its development in energy storage and become a leading provider of integrated PV-storage solutions [4]

Core Insights - EdgeMode, Inc. has announced the results of an internal review regarding legacy agreements and provided updates on its AI Data Center development in Spain [1] Internal Review of Legacy Agreements - The company identified issues in a share exchange agreement completed earlier this year and intends to pursue rescission based on newly discovered information [2] - The potential impact of this rescission represents less than 5.5% of the company's total AI data center development portfolio, which is currently 1.8 GW of gross capacity in Spain [3] Anti-Dilutive Effects of Pending Rescission Actions - The Board has terminated approximately 385 million unexercised stock options, eliminating 12.8% of potential dilution immediately [4] - If rescission is completed, the company expects to return up to 1.56 billion shares previously issued under the agreement to treasury [4] - These actions could collectively eliminate over 50% of potential and outstanding dilution, significantly increasing shareholder ownership percentage [5] Spain AI Data Center Development Portfolio Continues to Advance - The strategic AI Data Center portfolio in Spain, with a 1.5 GW IT development capacity, remains intact and is progressing on schedule [6] - The company anticipates announcing multiple milestones related to permitting approvals, power procurement, design and engineering updates, and early-stage client engagements in the coming quarters [6] Governance Measures to Support Stability - To ensure continuity during the transition, the company has established a Series D preferred class of stock to provide governance stability, which has no economic dilution effect on common stockholders [6] CEO Comment - The CEO stated that the steps taken strengthen the capital structure and allow the company to focus on advancing its AI Data Center development pipeline in Spain, positioning the company securely for future growth [7]

Group 1 - The company is hosting a Capital Markets Day on 12 May 2026, inviting institutional investors and analysts to attend [1] - The event will be a hybrid format, featuring live streaming and a recording available on the investor website post-event [1] - Limited seats are available for physical attendance at the event location in Hedehusene, Denmark [1] Group 2 - Contact information for investor relations is provided, including the name and contact details of the IR Coordinator [2]

Core Insights - Amplia Therapeutics Limited has reported an additional confirmed partial response in the ongoing ACCENT trial for metastatic pancreatic cancer, indicating progress in their clinical research [1][6] - The confirmed objective response rate (ORR) has reached 35% (19 out of 55 patients), which is significantly higher than the 23% ORR observed in the benchmark MPACT trial for gemcitabine and nab-paclitaxel alone [2][5] Company Overview - Amplia Therapeutics Limited is an Australian pharmaceutical company focused on developing a pipeline of Focal Adhesion Kinase (FAK) inhibitors targeting cancer and fibrosis, particularly in fibrotic cancers like pancreatic and ovarian cancer [4] - The company is advancing its lead candidate, narmafotinib, which is a potent and selective FAK inhibitor, currently being tested in the ACCENT trial in combination with gemcitabine and Abraxane for advanced pancreatic cancer [5] Clinical Trial Details - The ACCENT trial has achieved its primary endpoint with a confirmed response rate of 35%, surpassing the benchmark of 23% from the MPACT study [5] - An interim median progression-free survival (PFS) of 7.6 months has also been reported in the trial [5] - A second trial, AMPLICITY, is underway, investigating the combination of narmafotinib with the chemotherapy FOLFIRINOX in advanced pancreatic cancer patients [5]

Final Decision from European Commission Expected in Q1 2026 SOUTH SAN FRANCISCO, Calif., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending marketing authorization in the European Union (EU) for MYQORZO® (aficamten), a cardiac myosin inhibitor, for the treatment of symptomatic (New York Heart Association, NYHA, class II-III ...

Core Viewpoint - Rail Vision Ltd. has announced a strategic acquisition of 51% ownership in Quantum Transportation Ltd., aiming to enhance railway safety and data-related technologies through quantum computing and AI innovations [1][3]. Group 1: Acquisition Details - The acquisition is expected to close between late December 2025 and early January 2026, pending customary closing conditions [1]. - Rail Vision will issue ordinary shares representing approximately 4.99% of its issued and outstanding share capital to certain Quantum Transportation shareholders in exchange for their full holdings [4]. - A convertible loan of up to $700,000 will be extended to Quantum Transportation at an 8% annual interest rate to support its operations and development roadmap for the next 18 months [5]. Group 2: Technology and Innovation - Quantum Transportation holds an exclusive sublicense for a pending patent application in quantum error correction, which addresses challenges in noisy intermediate-scale quantum devices [2]. - The machine learning-based universal decoder technology from Quantum Transportation is expected to significantly improve quantum error correction, making it adaptable across various hardware platforms [6]. - Rail Vision aims to leverage this technology for transportation applications, enhancing capabilities in anomaly detection, predictive maintenance, and autonomous rail operations [7]. Group 3: Strategic Goals - The combination of Rail Vision's advanced vision and railway safety technologies with Quantum Transportation's quantum-AI based IP is anticipated to create technological synergies and accelerate innovation [3]. - The strategic acquisition is positioned to support long-term value creation for stakeholders by enhancing Rail Vision's current and future product lines [3].

Core Insights - The partnership between WELLE Environmental Group and Primech Holdings aims to innovate in industrial robotics and sustainable environmental technologies through a Joint Venture in Singapore [1][2][3] Group 1: Strategic Cooperation - WELLE and Primech Holdings will establish a Joint Venture to combine WELLE's environmental governance and bioenergy capabilities with Primech's operational experience and robotics expertise [2][3] - The Joint Venture will focus on developing specialized industrial robots for high-risk and complex environments, contributing to global carbon reduction goals [2][3] Group 2: Investment and Vision - WELLE has an option to invest in Primech AI until September 2026, highlighting a shared long-term vision for scaling robotics solutions across Asia [5] - Both organizations recognize the increasing global demand for intelligent automation in environmental and industrial operations, aiming to enhance safety, efficiency, and environmental performance [6] Group 3: Company Profiles - WELLE Environmental Group specializes in energy conservation and environmental protection, focusing on areas such as food waste utilization and biogas development [7] - Primech AI is dedicated to innovation in robotics, aiming to revolutionize the industry with impactful solutions [8] - Primech Holdings provides technology-driven facilities services, integrating eco-friendly practices and smart technology to enhance operational efficiency [10]